Skip to main content
SpringerLink
Log in

Genetic Engineering 3

  • Book
  • © 1982

Overview

Editors:
  1. Robert Williamson

    1. St Mary’s Hospital Medical School, University of London, UK

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Genetic Engineering: Principles and Methods (GEPM)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 39.99
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (4 chapters)

  1. Front Matter

    Pages i-xi
    Download chapter PDF

  2. Plasmid and phage M13 cloning vectors

    • Russell Thompson
    Pages 1-52

  3. Vectors based on bacteriophage lambda

    • W. J. Brammar
    Pages 53-81

  4. Expression of cloned genes in eukaryotic cells using vector systems derived from viral replicons

    • Peter W. J. Rigby
    Pages 83-141

  5. A comprehensive list of cloned eukaryotic genes

    • Kay E. Davies
    Pages 143-173
Back to top

Keywords

About this book

Like many genetic engineers, I have recently been receiving the atten­ tion of various venture capital companies, international drug houses and Members of Parliament. I will not discuss which of these approaches are most welcome, but it did cause me to consider the speed of advance in genetic engineering, and the implications of this rapid growth. There were few who anticipated it - only five years ago, most scientists thought applications would come at the end of the century, yet we see products such as insulin and interferon already available for clinical testing. In Europe in general and Britain in particular, this explosive growth in our own field has coincided with a general industrial depression and a marked reduction in funding for biomedical research. The brain drain from Britain is a serious matter, for we are losing the best of our younger scientists, on whom we would rely to train the next generation of molecular biologists. These volumes have come from British labs (mostly because I happen to be based in London, and my contacts and friends are here), and I feel that the quality of the con­ tributions also shows that our current research is of a high standard.

Editors and Affiliations

  • St Mary’s Hospital Medical School, University of London, UK

    Robert Williamson

Bibliographic Information

Publish with us

Policies and ethics

Back to top

Search

Navigation